lication of the Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation (NICE-SUGAR) trial in March 2009, which reported an increased 90-day mortality with IIT 7 . This study led to an increase in the recommended glucose range in critical illness (including the Surviving Sepsis Guidelines recommendation to treat blood glucose (BG) levels above 10.0 mmol/l 8 and the Society of Critical Care Medicine Guidelines recommendation that a BG >8.33 mmol/l trigger intervention to maintain BG below that level and absolutely below 10.0 mmol/l) 9 and ongoing debate about the interpretation of existing IIT literature and the ideal target glycaemic range in critical illness 10 .
The Geelong Hospital (TGH) ICU has had a written glucose control protocol in place since 2000. In february 2002, following publication of the first Leuven study on IIT 3 , the targeted glycaemic range was set at 4.4 to 7.0 mmol/l for all patients admitted to ICU. In April 2009, following publication of the NICE-SUGAR trial 7 , the target glycaemic range was increased to 7.1 to 9.0 mmol/l for all patients admitted to ICU. This protocol change offered a unique opportunity to assess whether translation of research into daily practice would be associated with outcome changes similar to those seen in a key large randomised controlled trial.
we aimed to examine the translation of intensive care glycaemic control evidence as obtained in the NICE-SUGAR trial into practice by studying glycaemic control and long-term outcomes in patients from a tertiary adult ICU.
MaTeRIaLS aNd MeTHOdS

Study setting and design
Ethics approval was obtained from the Barwon Health Human Research and Ethics Committee prior to commencement of the study (approval number 12/60). we conducted a retrospective, observational, before and after cohort study at TGH ICU, a level 3 tertiary, adult, mixed cardiac surgical, surgical and medical 19-bed ICU.
Participants
Participants included all adult patients admitted to TGH ICU during two 24-month periods, before the publication of NICE-SUGAR (1 February 2007 to 31 January 2009) and after (1 June 2009 to 31 May 2011).
Intervention
The ICU had a written, nurse-initiated glucose control protocol in place. The design of the protocol aimed to alter the insulin infusion rate up or down in relation to the absolute BG and rate of change of the BG. Intensive care nurses performed BG measurements at regular intervals, which ranged from 30 minutes to four-hourly depending on the stability and level of BG. Actrapid ® (Novo Nordisk Pharmaceuticals Pty Ltd, Bagsvaerd, denmark) insulin (50 units mixed with 0.9% saline to 50 ml in a 50 ml syringe) was infused using an Alaris ® GH Plus syringe pump (CareFusion Corporation, San Diego, CA, USA) via a dedicated central venous line lumen. BG measurements were whole-blood measurements performed using a blood gas analyser (aBL-625, Radiometer, Copenhagen, Denmark).
Detailed glucose control protocols are presented in Appendix 1 (available online). From February 2002 to March 2009, a modified IIT (mIIT) protocol with a target glycaemic range of 4.4 to 7.0 mmol/l was in place. From April 2009 on, the target glycaemic range was increased to 7.1 to 9.0 mmol/l, CGC. Along with the changes in the protocol, an education and implementation project occurred in the ICU.
Data collection
Data for this study were obtained through electronic data linkage of the TGH ICU electronic records (SLIC © ), TGH Clinical Information System (BOSSnet © , Core Medical Solutions, Rose Park, South Australia), and the Australian Institute of Health and welfare National death Index using indirect identifiers.
Baseline information collection included demographics, Acute Physiology and Chronic Health Evaluation II and III severity of illness scores, admission category, ICU interventions and outcomes (renal replacement therapy, mechanical ventilation, length-of-stay, outcome) and hospital interventions and outcomes (outcome, length-of-stay). Survival outcomes were obtained using an existing database link between the TGH ICU database and the National death Index. Blood glucose levels (BgL) were obtained by database linkage of SLIC © and BOSSnet © , with all BgLs performed during the ICU stay collected with time and date of recording.
The glycaemic outcome indices were based on the NICE-SUGAR trial 7 . Time-weighted glucose values were calculated based on the time difference between two consecutive measurements applied to the average of the two consecutive measurements. The rate of hypoglycaemia was defined as at least one Bg measurement ≤2.2 mmol/l (severe hypoglycaemia) or ≤3.9 mmol/l (moderate hypoglycaemia) during the ICU admission. Glycaemic variability was measured as standard deviation of BG measures in the before and after cohorts. Subgroups were identified as in previous IIT trials 3,5,7 including medical or surgical admission, ICU lengthof-stay longer than 48 hours and presence or absence of diabetes mellitus.
Statistical analysis
Statistical analysis was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). Baseline comparisons between groups were performed using chi-square tests for equal proportion and presented as percentages (number). Continuous, normally distributed variables were compared using student t-tests and presented as means (standard deviation), while non-normally distributed variables were compared using wilcoxon rank sum tests and reported as medians (interquartile range). Before and after time periods were initially compared using logistic regression, adjusting for patient illness severity and diagnosis, with results reported as odds ratios (95% confidence interval). To further account for temporal changes, segmented regression analysis of interrupted time series was performed on the number of events occurring each month before and after NICE-SUGAR, with the average Acute Physiology and Chronic Health Evaluation III score for all patients within each monthly period also included as a covariate to indirectly account for patient severity. Segmented regression analysis was performed by fitting a line for the before NICE-SUGAR period, a separate line for the after NICE-SUGAR trial period and a binomial term for before/after to determine whether there was significant vertical shift between the two periods.
A two-sided P value of 0.05 was considered to be statistically significant.
ReSuLTS
Of 5202 eligible patients, 4878 patients had BG measurements recorded during the four-year study period (before n=2546, after n=2332). The baseline characteristics of the cohorts are presented in Table 1 . The mIIT cohort had significantly lower severity of illness scores, a lower proportion of medical compared to surgical admission category and a similar number of patients with pre-existing diabetes mellitus compared to the CGC cohort.
Glycaemic control
The median time-weighted glucose levels were 6.98 (6.28 to 7.83) mmol/l with mIIT and 8.15 (7.17 to 9.14) mmol/l with CGC (P <0.0001) ( Table 1) . This represented a 17% relative increase in median timeweighted glucose concentration between cohorts. Similar increases were documented in mean (16%) and maximum glucose values (12%), with the largest increase observed in the minimum glucose value (25%). glucose variability did not change significantly between the two periods. The difference in glycaemic control between the two periods was present on the day of ICU admission and continued throughout the ICU stay, as represented in Figure 1 .
Analysis by subgroup revealed similar changes in glycaemic control in the mIIT and CGC cohorts, with an increase in time-weighted glucose, mean glucose, and minimum and maximum glucose observed in medical admissions, surgical admissions, ICU lengthof-stay >48 hours and diabetic and non-diabetic groups ( Table 2) .
Mortality
The 90-day mortality rate was higher in the mIIT cohort (15.4%) compared with the CGC cohort (13.3%) (P=0.037) (Table1). The adjusted 90-day odds ratio for mortality was 47% higher with mIIT (odds ratio 1.47 [95% confidence interval, 1.22 to 1.78] P <0.0001) ( Table 3) . A decrease in ICU, hospital and one-year mortality rate was also observed with CgC, which became significant after adjustment for patient illness severity and diagnosis ( Table 3 ). Segmented regression analysis confirmed these findings, with the number of deaths per month (90-day mortality attributed to the month of admission) declining from 17.7 (95% confidence interval, 15.4 to 20) per month during mIIT to 11.8 (95% confidence interval, 9.5 to 14.1) per month with CGC. The average reduction in the number of deaths per month was 5.90+2.11, P=0.008) (Table 4, Figure 2 ). This pattern continued, but was no longer significant at one year after ICU discharge ( Table 4 ). The adjusted mortality rates by subgroup are presented in Table 3 . The adjusted 90-day mortality rate was significantly lower in the CgC cohort in all subgroups. The reduction in mortality was also observed in the CGC cohort in all subgroups at ICU discharge, hospital discharge, 90 days and one year, with the only exception being the one-year mortality in non-diabetic patients. The reduction in mortality observed with CGC compared to mIIT decreased from ICU discharge to one year in all subgroups, with the exception of the diabetes mellitus subgroup, where an increase in effect was observed over time.
Hypoglycaemia
The incidence of severe and moderate hypoglycaemia decreased significantly (Table 5) . Overall, the incidence of severe hypoglycaemia decreased from 1.2 to 0.4% (P=0.004) and moderate hypoglycaemia decreased from 23.3 to 5.9% (P <0.0001). Subgroup analysis revealed a decreased incidence of severe and moderate hypoglycaemia in all subgroups with CGC compared to mIIT. Both logistic and segmented regression analysis adjusting for covariates confirmed that episodes of moderate and severe hypoglycaemia were significantly higher with mIIT compared to CGC and remained higher in all subgroups ( Table 6) .
DISCUSSION
This study describes the translation of glycaemic control evidence into clinical practice in a large single-centre ICU population. The transition from an mIIT protocol to a CGC protocol was associated with a significant increase in glycaemic indices, reduction in hypoglycaemic episodes and a significant reduction in 90-day mortality.
The glycaemic control observed in this study allows the before and after NICE-SUGAR trials cohorts Data are shown as % (no.). * defined as number of patients with one or more episodes of blood glucose <2.2 mmol/l, # defined as number of patients with one or more episodes of blood glucose <3.9 mmol/l, ICU length-of-stay in hours, mIIT=modified intensive insulin therapy, CGC=conventional glucose control, DM=diabetes mellitus, ICu=intensive care unit, LOS=length-of-stay. to be characterised as mIIT and CGC. In the before NICE-SUGAR cohort, the IIT target glycaemic range was modified from the Leuven IIT range (4.4 to 6.0 mmol/l) 3, 5 to a higher range (4.4 to 7.0 mmol/l) in an attempt to minimise the risk of hypoglycaemia. As a consequence, the observed average time-weighted glucose was 6.98 mmol/l, higher than in the NICE-SUGAR IIT arm time-weighted glucose (6.38 mmol/l) and higher than the upper limit of the 95% confidence interval time-averaged mean glucose value (6.44 mmol/l) 7 . In our CGC cohort, the average time-weighted glucose was 8.15 mmol/l, similar to the NICE-SUGAR control arm (7.99 mmol/l). Thus, in our study, the difference in average time-weighted glucose between mIIT and CGC was 1.17 mmol/l. This is 72.6% of the difference observed between the NICE-SUGAR treatment groups (1.61 mmol). In parallel, the unadjusted absolute 90-day mortality difference in our study was 2%, which is 76.9% of the absolute difference in 90-day mortality seen in the NICE-SUGAR trial (2.6%). defining the ideal glycaemic range in critical illness remains an unresolved issue. The NICE-SUGAR trial reported an increased 90-day mortality in critically ill patients receiving IIT, an unexpected contrast to the Leuven IIT trials 3, 7 , and the authors recommended against aiming for tight glycaemic control. In response to the conflicting IIT evidence, the American Diabetes Association 2012 guidelines recommended a target glucose range of 7.8 to 10.0 mmol/l in critical illness, or more stringent goals, such as 6.1 to 7.8 mmol/l for selected patients, as long as this could be achieved without significant hypoglycaemia 11 . More recently, the 2012 Surviving Sepsis guidelines recommend interventions for BgLs above 10.0 mmol/l 8 , while the 2012 intensive insulin therapy clinical practice guidelines recommend that a BG >8.33 mmol/l in critically ill patients should trigger intervention to preferably maintain BG below this level, and absolutely below 10.0 mmol/l, although describing the evidence as weak 9 . In summary, there is ongoing debate about the interpretation of existing IIT literature; the ideal target glycaemic range in critical illness 10, 12 ; and whether the potential harm associated with IIT results from lower mean glucose, increases in insulin use, an increase in hypoglycaemia rate or other factors.
In this study, the mIIT protocol resulted in higher mean BgLs and also lower rates of hypoglycaemia than described in the treatment arms of previous IIT studies, providing a level of glycaemic control just above that of IIT. The incidence of severe hypoglycaemia observed in the mIIT cohort was 1.2%, a low value compared to the treatment arms of the IIT randomised controlled trials (Leuven medical ICU 18.7% 5 , Leuven surgical ICu 5.0% 3 , efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis 12.1% 6 , NICE-SUGAR 6.8% 7 ) and observational studies of IIT (2.3%) 13 . Despite the reduced rate of hypoglycaemia observed in the mIIT protocol compared to the treatment arms in previous IIT studies, we observed an increased risk of dying with mIIT compared to CGC, suggesting that the hypoglycaemia rate alone may not be sufficient to explain the increased risk associated with the pursuit of a lower glycaemic range. In addition, the lack of any change in glycaemic variability with the transition from mIIT to CGC also suggests that changes in variability cannot logically be used to explain the changes in mortality.
The changes in mortality associated with the transition from mIIT to CgC seen in this study reflect almost exactly those seen in the NICE-SUGAR trial and suggest that the lower glycaemic range achieved with mIIT is not superior to CGC. Modified IIT was associated with an increased risk of mortality compared to CGC in the entire cohort at 90 days, with the association strengthening after risk adjustment. In contrast to the Leuven trials 3,5 , this relationship was strongest in medical ICU patients. In the patient group most comparable to the NICE-SUGAR trial (ICU length-of-stay of longer than 48 hours), we observed a significant decrease in 90-day mortality from 23 to 19%, compared to the NICE-SUGAR 90-day mortality rates of 27.5% (IIT) versus 24.9% (conventional) 7 . In addition, the presence of pre-existing diabetes mellitus altered the association of glycaemic control with mortality, with a significant decrease in mortality observed in patients with diabetes but not patients without diabetes when changing from mIIT to CGC.
An association between moderate glucose control and decreased risk of mortality in patients without diabetes has been described recently in a large retrospective study of patients receiving an insulin eProtocol, with clinicians allowed to select a target range of 4.4 to 6.1 mmol/l or 5.0 to 7.8 mmol/l. In contrast to our study, moderate glucose control was associated with a higher mortality in patients without diabetes. The selection of glucose target range by clinicians introduced the possibility of selection bias, with higher Acute Physiology and Chronic Health Evaluation II scores and a higher proportion of females in the moderate glucose control group 14 .
The pattern of this mortality relationship over time was also different in the presence of pre-existing diabetes, increasing over time compared to the opposite relationship observed in all other groups. This difference in outcomes relating to diabetes status in critical illness and glycaemic range has been recently described in a large ICU cohort study, suggesting that patients with diabetes may be at greater risk when lower glucose targets are pursued than those without diabetes 15 .
Our ability to report on long-term mortality outcomes is unique in the literature surrounding glycaemic control in critical illness. The risk-adjusted mortality remained higher with mIIT compared to CGC even at one year in the entire ICU population and all subgroups, with the exception being patients without diabetes mellitus. The factors contributing to this observed decrease in long-term mortality are not defined by this study, although severity of illness, diagnostic category and time-related changes to mortality were accounted for. The segmented regression analysis finding, that the decrease in mortality from before to after NICE-SUGAR was no longer significant at one year, may suggest that the observed change in one-year mortality was partly due to the temporal change over time. It may also indicate that one-year mortality is less dependent upon patient illness severity.
The strengths of this study include the large size of the study population enabling studying of patient subgroups and time series analysis; the heterogeneous composition of the study population, increasing the external validity; the availability of all glucose measurements during the ICU stay along with the times of determination to allow calculation of diverse glycaemic metrics used in the large randomised control trials of IIT; a comprehensive dataset that includes severity of illness scores, comorbidities and interventions; and the data linkage between hospital and national databases providing long-term outcomes for all patients.
There are limitations to this study. The data were collected prospectively for purposes other than this analysis. when accessed retrospectively, the variables available for this study were limited. Accordingly, some baseline characteristics, comorbidities, interventions and other factors that may alter outcomes or glycaemic control cannot be accounted for. The two study populations differed in their years of observation, and it was not possible to account for general improvements in care that occurred over the time period and improved patient outcomes. Finally, the increase in mortality in the NICE-SUGAR study primarily reflected more cardiovascular deaths in the IIT group. In this study we were unable to obtain cause of death and, accordingly, were unable to further examine this relationship.
CONCLuSIONS
we report the impact of the translation of critical illness glycaemic evidence into practice in a large adult population. we found a reduced mortality associated with a change from mIIT to CGC. mIIT was not superior to CGC, despite a lower hypoglycaemia rate than seen in previous IIT trials. Our findings support the continued use of CGC as described in the NICE-SUGAR trial.
